MX2022012067A - 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad agonista de gpr52. - Google Patents

3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad agonista de gpr52.

Info

Publication number
MX2022012067A
MX2022012067A MX2022012067A MX2022012067A MX2022012067A MX 2022012067 A MX2022012067 A MX 2022012067A MX 2022012067 A MX2022012067 A MX 2022012067A MX 2022012067 A MX2022012067 A MX 2022012067A MX 2022012067 A MX2022012067 A MX 2022012067A
Authority
MX
Mexico
Prior art keywords
phenoxyazetidin
pyrazines
gpr52
substituted
agonistic activity
Prior art date
Application number
MX2022012067A
Other languages
English (en)
Spanish (es)
Inventor
Kai Gerlach
Marco Ferrara
Yifeng Xiong
Barbara Bertani
Frank Runge
Graeme Semple
Giacomo Fossati
Scott Hobson
Julian Wippich
Uta Friederike Lessel
Ursula Mueller-Vieira
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2022012067A publication Critical patent/MX2022012067A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2022012067A 2020-03-30 2021-03-29 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad agonista de gpr52. MX2022012067A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (1)

Publication Number Publication Date
MX2022012067A true MX2022012067A (es) 2022-10-13

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012067A MX2022012067A (es) 2020-03-30 2021-03-29 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad agonista de gpr52.

Country Status (20)

Country Link
US (1) US11780827B2 (cg-RX-API-DMAC7.html)
EP (1) EP4126850B1 (cg-RX-API-DMAC7.html)
JP (1) JP7617134B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220161454A (cg-RX-API-DMAC7.html)
CN (1) CN115697997B (cg-RX-API-DMAC7.html)
AR (1) AR121675A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021250303A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018996A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176265A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014886A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220554A (cg-RX-API-DMAC7.html)
DO (1) DOP2022000203A (cg-RX-API-DMAC7.html)
EC (1) ECSP22080683A (cg-RX-API-DMAC7.html)
IL (1) IL296823A (cg-RX-API-DMAC7.html)
JO (1) JOP20220235A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022012067A (cg-RX-API-DMAC7.html)
PE (1) PE20221918A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552553A1 (cg-RX-API-DMAC7.html)
TW (1) TW202204343A (cg-RX-API-DMAC7.html)
WO (1) WO2021198149A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use
WO2023041432A1 (en) 2021-09-14 2023-03-23 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
CN119143731B (zh) * 2024-09-13 2025-08-26 中国海洋大学 一种吡嗪酰胺类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2361149A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Aromatic amides
JPWO2009107391A1 (ja) 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
EP2298731A4 (en) 2008-06-25 2011-09-21 Takeda Pharmaceutical AMIDE COMPOUND
EP2518054A1 (en) * 2009-12-24 2012-10-31 Takeda Pharmaceutical Company Limited Amide compound
EP2530078A1 (en) 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
WO2011145735A1 (ja) 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
MX373876B (es) * 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Also Published As

Publication number Publication date
AU2021250303A1 (en) 2022-09-22
US11780827B2 (en) 2023-10-10
IL296823A (en) 2022-11-01
JOP20220235A1 (ar) 2022-09-28
DOP2022000203A (es) 2022-11-30
ECSP22080683A (es) 2022-11-30
CA3176265A1 (en) 2021-10-07
TW202204343A (zh) 2022-02-01
CO2022014886A2 (es) 2022-10-31
PE20221918A1 (es) 2022-12-29
KR20220161454A (ko) 2022-12-06
JP2023522307A (ja) 2023-05-30
BR112022018996A2 (pt) 2022-11-01
WO2021198149A1 (en) 2021-10-07
CN115697997B (zh) 2024-07-30
EP4126850B1 (en) 2024-04-17
AR121675A1 (es) 2022-06-29
EP4126850A1 (en) 2023-02-08
US20220356172A1 (en) 2022-11-10
CR20220554A (es) 2023-01-09
CN115697997A (zh) 2023-02-03
PH12022552553A1 (en) 2024-01-03
JP7617134B2 (ja) 2025-01-17

Similar Documents

Publication Publication Date Title
JOP20210307A1 (ar) مثبطات جسيم التهابي nlrp3
SA522432734B1 (ar) مركبات أمينو كينولون تحمل بدائل تستخدم كمثبطات لـثنائي أسيل غليسرول كيناز ألفا من أجل تنشيط المناعة
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
GEAP202515818A (en) Amino quinazoline derivatives as p2x3 inhibitors
PH12022552987A1 (en) Antagonists of the adenosine a2a receptor
PH12022552553A1 (en) Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity
PH12021500034A1 (en) Compounds useful in hiv therapy
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
TN2018000372A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions.
PH12021552004A1 (en) Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
PH12021552375A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MX2023006881A (es) Antagonistas del receptor de adenosina a2a.
MX2025012370A (es) Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta
MX2025012705A (es) Complejos cristalinos entre velagliflozina y agentes formadores de cocristales seleccionados, metodos para su preparacion y su uso en la preparacion de medicamentos
PH12021552680A1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
ZA202211253B (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
AR127031A1 (es) Derivados de 3-fenoxiazetidin-1-il-heteroaril pirrolidina y el uso de estos como medicamento
GEP20257771B (en) Compounds and compositions as sppl2a inhibitors
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects
PH12022551012A1 (en) 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease
ZA202405279B (en) Heteroaryl derivative and use thereof